Igenomix→Vitrolife
Acquisition · Cash + Stock · VITR · announced Jul 8, 2021
Announced
Jul 8, 2021
Closed
Nov 30, 2021
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2021, year precision · rounding grid ±$100M · Vitrolife press release — Igenomix acquisition, 2021
Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Target
Igenomix
Diagnostics · Diagnostic / genomic
HQ Valencia, Spain · Founded 2011
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
Acquirer
Vitrolife (VITR)
Fertility
HQ Gothenburg, Sweden
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Combined IVF medical devices with reproductive genetic testing to create global reproductive health leader — Igenomix operated 26 labs across 26 countries
Evidence ladder
Secondary (press / IR)
Cision/Vitrolife press release (Jul 8, 2021)
Secondary (press / IR)
PR Newswire (Nov 30, 2021)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
- Pre-deal valuation sourced from: Vitrolife press release — Igenomix acquisition, 2021. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | same evidence class | |
| Counsyl | Myriad Genetics | May 28, 2018 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| nVision Medical | Boston Scientific | Apr 16, 2018 | ||
| PreventionGenetics | Exact Sciences | Jan 9, 2022 | ||
| Gateway Genomics | Myriad Genetics | Nov 1, 2022 |
Other verified deals by Vitrolife
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| eFertility (STB Zorg) | Vitrolife | May 2, 2024 | Undisclosed | Fertility |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Igenomix (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.